NASDAQ:ANIK - Anika Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$44.60 -0.45 (-1.00 %)
(As of 06/18/2018 02:42 PM ET)
Previous Close$45.05
Today's Range$44.0503 - $44.96
52-Week Range$30.91 - $69.81
Volume130,986 shs
Average Volume164,490 shs
Market Capitalization$664.27 million
P/E Ratio22.76
Dividend YieldN/A
Beta1.72

About Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics logoAnika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. has a strategic collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst to develop a therapy for rheumatoid arthritis. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Receive ANIK News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ANIK
CUSIP03525510
Phone781-457-9000

Debt

Debt-to-Equity RatioN/A
Current Ratio14.74
Quick Ratio13.13

Price-To-Earnings

Trailing P/E Ratio22.76
Forward P/E Ratio41.30
P/E Growth4.17

Sales & Book Value

Annual Sales$113.42 million
Price / Sales5.80
Cash Flow$2.2825 per share
Price / Cash19.54
Book Value$17.97 per share
Price / Book2.48

Profitability

EPS (Most Recent Fiscal Year)$1.96
Net Income$31.81 million
Net Margins17.64%
Return on Equity10.05%
Return on Assets9.32%

Miscellaneous

Employees123
Outstanding Shares14,740,000

Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics Inc (NASDAQ:ANIK) released its earnings results on Wednesday, May, 2nd. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of $0.25 by $0.71. The biotechnology company earned $21.30 million during the quarter, compared to analysts' expectations of $24.34 million. Anika Therapeutics had a return on equity of 10.05% and a net margin of 17.64%. The business's revenue was down 9.0% on a year-over-year basis. During the same period last year, the business earned $0.37 earnings per share. View Anika Therapeutics' Earnings History.

When is Anika Therapeutics' next earnings date?

Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Anika Therapeutics.

What price target have analysts set for ANIK?

3 brokerages have issued 12 month target prices for Anika Therapeutics' stock. Their forecasts range from $39.00 to $68.00. On average, they anticipate Anika Therapeutics' share price to reach $53.50 in the next year. View Analyst Ratings for Anika Therapeutics.

What are Wall Street analysts saying about Anika Therapeutics stock?

Here are some recent quotes from research analysts about Anika Therapeutics stock:
  • 1. According to Zacks Investment Research, "Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. " (5/7/2018)
  • 2. Barrington Research analysts commented, "We expect gross margin to bounce back by a few hundred basis points as the year progresses." (5/4/2018)

Are investors shorting Anika Therapeutics?

Anika Therapeutics saw a increase in short interest in May. As of May 31st, there was short interest totalling 2,158,837 shares, an increase of 50.8% from the May 15th total of 1,431,139 shares. Based on an average daily trading volume, of 218,529 shares, the short-interest ratio is presently 9.9 days. Approximately 15.0% of the shares of the company are sold short.

Who are some of Anika Therapeutics' key competitors?

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the folowing people:
  • Mr. Joseph G. Darling, CEO, Pres & Director (Age 60)
  • Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 43)
  • Dr. Edward S. Ahn, Chief Technology & Strategy Officer (Age 46)
  • Mr. Richard Hague, Chief Commercial Officer (Age 58)
  • Mr. Charles Sherwood III, VP & Corp. Legal Counsel

Has Anika Therapeutics been receiving favorable news coverage?

News stories about ANIK stock have trended positive this week, Accern reports. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Anika Therapeutics earned a daily sentiment score of 0.26 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 47.13 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.96%), Kayne Anderson Rudnick Investment Management LLC (11.58%), Dimensional Fund Advisors LP (6.31%), SHERWOOD CHARLES H (5.15%), Stifel Financial Corp (1.76%) and Wells Fargo & Company MN (1.48%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson, Joseph I Bower and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics.

Which major investors are selling Anika Therapeutics stock?

ANIK stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., BNP Paribas Arbitrage SA, Fisher Asset Management LLC, Spark Investment Management LLC, Russell Investments Group Ltd., KBC Group NV, Virginia Retirement Systems ET AL and Barclays PLC. Company insiders that have sold Anika Therapeutics company stock in the last year include Charles H Sherwood and Richard Hague. View Insider Buying and Selling for Anika Therapeutics.

Which major investors are buying Anika Therapeutics stock?

ANIK stock was purchased by a variety of institutional investors in the last quarter, including Stifel Financial Corp, Kayne Anderson Rudnick Investment Management LLC, Millennium Management LLC, BlackRock Inc., Baird Financial Group Inc., Dimensional Fund Advisors LP, 6 Meridian and WINTON GROUP Ltd. View Insider Buying and Selling for Anika Therapeutics.

How do I buy shares of Anika Therapeutics?

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $44.60.

How big of a company is Anika Therapeutics?

Anika Therapeutics has a market capitalization of $664.27 million and generates $113.42 million in revenue each year. The biotechnology company earns $31.81 million in net income (profit) each year or $1.96 on an earnings per share basis. Anika Therapeutics employs 123 workers across the globe.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]


MarketBeat Community Rating for Anika Therapeutics (ANIK)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  144 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  254
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe ANIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.